TRANSGENE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.21 EUR | -5.47% |
|
-12.45% | -11.68% |
| Apr. 10 | Transgene: presents vaccine results at AACR | CF |
| Mar. 28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 170 | 128.9 | 137.9 | 247.8 | 164.8 | 121.7 | 121.7 | - |
| Enterprise Value (EV) 1 | 212.7 | 114.3 | 129.9 | 214.9 | 151.4 | 139.4 | 138.1 | 160.1 |
| P/E ratio | 21 x | -6.74 x | -7.85 x | -12.1 x | -5.02 x | -6.23 x | -8.64 x | -5.76 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 3.96 x | 9.39 x | 13.9 x | 14.2 x | 15.9 x | 17.4 x | 3.06 x | 2.44 x |
| EV / Revenue | 4.96 x | 8.32 x | 13.1 x | 12.3 x | 14.6 x | 17.6 x | 3.47 x | 3.21 x |
| EV / EBITDA | 23.4 x | -4.63 x | -5.85 x | -10.2 x | -5.37 x | -4.9 x | -11.8 x | -8.47 x |
| EV / FCF | -6.4 x | -4.73 x | -4.39 x | -6.59 x | -6.94 x | -1,408 x | -11 x | -8 x |
| FCF Yield | -15.6% | -21.1% | -22.8% | -15.2% | -14.4% | -0.07% | -9.12% | -12.5% |
| Price to Book | 4.63 x | 1.96 x | 2.74 x | 3.69 x | 4.38 x | -30.3 x | -6.72 x | -3.03 x |
| Nbr of stocks (in thousands) | 62,276 | 83,190 | 83,677 | 97,576 | 99,370 | 100,566 | 100,566 | - |
| Reference price 2 | 2.730 | 1.550 | 1.648 | 2.540 | 1.658 | 1.210 | 1.210 | 1.210 |
| Announcement Date | 3/20/19 | 3/11/20 | 3/10/21 | 3/16/22 | 3/16/23 | 3/27/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 42.92 | 13.73 | 9.915 | 17.41 | 10.34 | 7.9 | 39.8 | 49.8 |
| EBITDA 1 | 9.101 | -24.68 | -22.21 | -21 | -28.22 | -28.48 | -11.7 | -18.9 |
| EBIT 1 | 7.368 | -25.45 | -23.99 | -23.52 | -29.9 | -30.05 | -15.7 | -23.9 |
| Operating Margin | 17.17% | -185.35% | -241.99% | -135.1% | -289.1% | -380.34% | -39.45% | -47.99% |
| Earnings before Tax (EBT) | 8.026 | - | -17.23 | -19.54 | -32.8 | - | - | - |
| Net income 1 | 8.026 | -18.8 | -17.23 | -19.54 | -32.8 | -22.33 | -13.8 | -21.1 |
| Net margin | 18.7% | -136.93% | -173.79% | -112.19% | -317.13% | -282.63% | -34.67% | -42.37% |
| EPS 2 | 0.1300 | -0.2300 | -0.2100 | -0.2100 | -0.3300 | -0.2200 | -0.1400 | -0.2100 |
| Free Cash Flow 1 | -33.22 | -24.14 | -29.59 | -32.61 | -21.84 | -0.099 | -12.6 | -20 |
| FCF margin | -77.4% | -175.81% | -298.48% | -187.3% | -211.12% | -1.25% | -31.66% | -40.16% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/20/19 | 3/11/20 | 3/10/21 | 3/16/22 | 3/16/23 | 3/27/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2022 S2 |
|---|---|---|
| Net sales 1 | - | 4.257 |
| EBITDA | - | - |
| EBIT 1 | - | -15.07 |
| Operating Margin | - | -353.98% |
| Earnings before Tax (EBT) 1 | - | -17.52 |
| Net income 1 | -15.28 | -17.52 |
| Net margin | - | -411.67% |
| EPS 2 | -0.1500 | -0.1800 |
| Dividend per Share | - | - |
| Announcement Date | 9/7/22 | 3/16/23 |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 42.7 | - | - | - | - | 1.63 | 16.4 | 38.4 |
| Net Cash position 1 | - | 14.6 | 7.99 | 32.9 | 13.3 | - | - | - |
| Leverage (Debt/EBITDA) | 4.689 x | - | - | - | - | -0.0572 x | -1.402 x | -2.032 x |
| Free Cash Flow 1 | -33.2 | -24.1 | -29.6 | -32.6 | -21.8 | -0.1 | -12.6 | -20 |
| ROE (net income / shareholders' equity) | 24.8% | -36.7% | -29.7% | -33.1% | -62.5% | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.5900 | 0.7900 | 0.6000 | 0.6900 | 0.3800 | -0.0400 | -0.1800 | -0.4000 |
| Cash Flow per Share | -0.4300 | - | - | - | - | - | - | - |
| Capex | 1.4 | 1.73 | 0.85 | 0.69 | 1.54 | - | 4.8 | 6 |
| Capex / Sales | 3.27% | 12.6% | 8.59% | 3.94% | 14.84% | - | 12.06% | 12.05% |
| Announcement Date | 3/20/19 | 3/11/20 | 3/10/21 | 3/16/22 | 3/16/23 | 3/27/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.21
EUR
Average target price
3.5
EUR
Spread / Average Target
+189.26%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.68% | 130M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- TNG Stock
- Financials Transgene
